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Abstract 
Background: Monocytes play an important role in immune and inflammatory diseases and monocyte subsets are 
predictors of disease in certain conditions. Expression of the chemokine receptors, CCR2 and  CX3CR1 on monocyte 
subsets relates to their function and can be used in their characterization. Our objective was to determine whether 
CD14, CD16, CCR2 and  CX3CR1 on monocyte subsets are potential indicators of asthma severity.
Methods: Blood samples were collected from Saudi Arabian patients with asthma and normal healthy individuals. 
Six‑color flow‑cytometry phenotypic analysis was used to identify human blood monocyte subsets, based on their 
expression of CD14 and CD16 following CD45 gating. Expression of CCR2 and  CX3CR1 was analysed on classical 
 (CD14++CD16−), intermediate  (CD14++CD16+) and non‑classical  (CD14+CD16++) subsets and correlated with 
disease severity.
Results: We demonstrated a significant increase in percentage of total CD45‑positive monocytes in the blood of 
patients with severe asthma, but the proportion of the individual monocyte subsets was not significantly changed 
when patients with mild, moderate and severe asthma were compared with healthy individuals. CD16 expression 
(mean fluorescence intensity, MFI) was decreased on intermediate and non‑classical subsets in patients with severe 
asthma compared to healthy controls.  CX3CR1 expression was also lower, with a lower percentage of cells expressing 
 CX3CR1 in the non‑classical  CD14
+CD16++ subset in all patients with asthma and this was inversely related to the 
percentage of cells expressing CCR2.
Conclusions: CCR2 expression on monocytes indicated a tendency toward more phagocytic monocytes in patients 
with asthma. The differential expression of CD16,  CX3CR1 and CCR2 on monocyte subsets in peripheral blood 
indicates modulation of the inflammatory response and suggests a role for monocytes in asthma pathogenesis.
Keywords: Saudi Arabia, Chemokine receptor, Flow cytometry, CD14, Biomarker
© The Author(s) 2019. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creat iveco mmons .org/licen ses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Bronchial asthma, a chronic inflammatory disorder 
characterized by reversible airway obstruction and 
hyperresponsiveness [1], is one of the commonest 
chronic disorders in the world [2]. Its prevalence and 
symptoms vary in different geographical locations and it 
affects over two million people in Saudi Arabia. Although 
therapeutic options have improved, there are still 
unnecessary fatalities and there is a clear need to improve 
treatment strategies and define better biomarkers to 
identify patients at risk.
Allergic inflammation in asthma is characteristically 
associated with T helper (Th) cell and eosinophil 
infiltration in the bronchial mucosa [3]. Antigen-specific 
Th2 lymphocytes play a critical role in the generation of 
allergic inflammation through the release of cytokines, 
such as interleukin (IL)-4, IL-5, IL-9, and IL-13 [4, 5], 
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which promote the activation and survival of eosinophils. 
However, monocytes are also likely to play a role due to 
increased production of monocyte-derived cytokines and 
mediators involved in oxidative stress, and in determining 
subsequent macrophage/dendritic cell and T helper cell 
phenotype and function [6, 7]. To date monocytes have 
received little attention in asthma pathogenesis although 
newly recruited monocyte-derived macrophages in the 
airway have been shown to be linked to eosinophilic airway 
inflammation [8]. Decrease in eosinophil recruitment 
in macrophage-depleted mice is thought to be due to 
reduction in macrophage chemokine production leading 
to altered recruitment of Th2 cells [8]. As a key immune 
cell in the bloodstream monocytes have been used to 
characterise severity of inflammation in other disorders 
including ischemic stroke and allergic rhinitis [7, 9, 10].
Human monocytes are heterogeneous and are 
classified into different subsets defined by the extent of 
their cell surface expression of CD14 and CD16, with 
associated differences in function and phenotype related 
to the intensity of expression of these markers. The 
major subset, termed classical monocytes, consists of 
 CD14highCD16negative  (CD14++CD16−) monocytes, while 
the CD16 expressing monocytes are usually divided into a 
 CD14highCD16low  (CD14++CD16+) intermediate subset and 
a  CD14lowCD16high  (CD14+CD16++) non-classical subset 
[11–13]. Differential expression of the chemokine receptors 
CCR2 and  CX3CR1 is associated with these human 
monocyte subsets with the classical  CD14++CD16− subset 
predominantly expressing CCR2 and the non-classical 
 CD14+CD16++ subset showing lower CCR2 expression and 
expressing significantly higher  CX3CR1 [14–16].
These subsets have different functions with the 
 CD14++CD16− subset showing predominantly a 
phagocytic phenotype,  CD14++CD16+ an inflammatory/
antigen presenting phenotype and  CD14+CD16++ 
a patrolling phenotype in blood vessels that also has 
ability to present antigen [17, 18]. The  CD14++CD16+ 
and  CD14+CD16++ subsets account for only 5–15% 
of all human monocytes, but their frequency increases 
significantly in certain inflammatory conditions [17, 19–
21]. One study of patients with asthma in Poland showed 
a significant increase in the frequency of  CD14++CD16+ 
monocytes in patients with severe asthma compared to 
healthy controls or patients with mild and moderate 
asthma [22] and it was suggested that this increase in 
the intermediate population might be a useful biomarker 
for asthma severity. However, whether this is universally 
applicable is unknown.
Our aims were firstly to test, in a different population, 
the hypothesis that increase in the percentage of 
intermediate monocytes is associated with severe asthma 
and secondly to determine whether expression of the 
chemokine receptors, CCR2 and  CX3CR1, on monocyte 
subsets can act as indicators of asthma severity. We 
used flow cytometry to compare monocyte populations 
in Saudi Arabian adults with asthma and healthy age 
matched controls and analysed data to identify any 
associations between subset populations and asthma 
severity.
Methods
Participants
The participants were all from Saudi Arabia and 
included 35 healthy, non-smoking adult volunteers 
with no history of asthma or of any respiratory disease 
as controls (Table  1). None of the control subjects 
had suffered from any febrile illness during the last 3 
months or were taking any medication. Seventy-six 
patients routinely attending asthma clinics while in a 
non-attack state were studied and presented with mild 
asthma (22 patients), moderate asthma (32 patients) 
and severe asthma (22 patients) (Tables 1 and 2).
Severity of asthma was classified according to the Saudi 
Initiative for Asthma (SINA) guidelines based on Global 
Initiative for Asthma (GINA) criteria [23, 24]. Assessment 
of asthma severity was based on the treatment steps 
required to control symptoms and exacerbations.
Mild asthma controlled asthma at step 1 or 2 that 
needs reliever treatment, monotherapy of low-dose 
inhaled corticosteroids (ICS), or leukotriene receptor 
antagonist (LTRA).
Moderate asthma controlled asthma where the 
patients are on combination of ICS/long-acting beta 2 
agonist (LABA) or other alternative options at step 3.
Severe asthma severe uncontrolled asthma at 
presentation (step 4 or 5) where patients require 
treatment with combination of high-dose ICS/LABA 
with or without add-on treatment.
Ethical standards
All participants with asthma were selected from the 
respiratory outpatient clinic at King Khalid University 
Hospital. The study protocol was approved by the 
Institutional Review Board of King Khalid University 
Hospital, Ethics Committee, and signed informed 
consent was obtained from all participants.
Flow cytometry
Sample collection and preparation
Five ml of venous blood was withdrawn from the cubital 
vein into EDTA-anticoagulant, transferred to a 50  ml 
centrifuge tube and centrifuged for 4 min at 431×g. The 
supernatant was discarded and 10  ml of red blood cell 
lysing solution (Sigma Aldrich R7757) was added and 
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incubated for 20 min at room temperature (RT) followed 
by centrifugation for 4 min at 431×g. Re-suspended cell 
pellets were washed twice with 15  ml of FACS buffer 
(phosphate buffered saline (PBS) and 2% fetal bovine 
serum FBS) for 4 min at 431×g and re-suspended in 1 ml 
of FACS buffer.
Compensation, optimization and controls
Cytometer setup tracking (CST) research beads were 
used as a quality control for the instrument to improve 
the automated cytometer setup and performance. 
Compensation beads were used to ensure the integrity of 
the fluorochromes being used in the experiment before 
data acquisition. To optimize the fluorescence for the multi-
color flow cytometric analysis, fluorescence compensation 
was run first for each fluorochrome being analysed.
In order to achieve consistent and reproducible results, 
and to minimize bleeding between the different dyes, 
optimization experiments were performed for surface 
markers (Alexa-700, BV510, BV421, Alexa-647, PE, and 
DAPI) prior to sample acquisition.
Table 1 Demographic and clinical characteristics of subjects with asthma and healthy controls
Data are presented in the form of numbers or percentage (%)
FEV1 forced expiratory volume in 1 s; SHS second hand smoke; ICS inhaled corticosteroid; LABA long acting β2 agonist; SABA short acting β2 agonist; PRN as needed
Healthy control Asthma
Mild Moderate Severe
N 35 22 32 22
Mean, age ±SD 39 ± 12.86 39 ± 11.64 46 ± 16.1 52 ± 12.73
Gender, F|M 15|20 13|9 19|13 16|6
Asthma duration, years (mean) – 18.33 16.03 21.48
Family history, n (%) – 15 (68.2) 17 (53.1) 15 (68.2)
FEV% – 93 77.38 69.25
History of smoking, n (%) 0 1 (4.5) 1 (3.1) 0
Current smoking, n (%) 0 3 (13.6) 3 (9.4) 2 (9.1)
SHS, n (%) 2 (9.1) 2 (6.25) 2 (9.1)
Treatment
 ICS/LABA combined inhaler
  Budesonide/formoterol (160 µg/4.5 µg)
   n (%) 0 0 23 (84.4) 15 (77.3)
   n/day 2/day 2/day
  Fluticasone/Salmeterol (125 µg/25 µg)
   n (%) 0 0 9 (28.1) 7 (31.8)
  n/day 2/day 2/day
 SABA
  Salbutamol (200 µg)
   n (%) 0 1 (4.5) 3 (9.4) 22 (100)
   n/day 2/day 4/day 2/day
   PRN 21 (95.4) 29 (90.6) 0
 Tiotropium
  Spiriva (18 µg)
   n (%) 0 0 0 15 (68.2)
   n/day 1/day
 Montelukast
  Singulair (10 µg)
   n (%) 0 0 12 (37.5) 20 (90.9)
   n/day, course 1 course 1/day
 Anti‑IgE
  Omalizumab (300 mg)
   n (%) 0 0 0 19 (86.4)
   n/month 1/month
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Table 2 Co-morbidities and laboratory characteristics of asthma patients
Data are presented in the form of numbers or percentage (%)
n number of patients; Percentage of number of patients is shown in parentheses. GERD gastroesophageal reflux disease
“–” was not measured for mild asthma patients
a Total IgE normal range, 0–100 Ku/l
b Eosinophil percentage of leukocyte count normal range, 0–6%
c Eosinophil count normal range, 0.2–0.8 × 109/l
d Neutrophil percentage normal range, 40–75
e Neutrophil count normal range, 2–7.5 × 109/l
f Lymphocyte percentage normal range, 20–45
g Lymphocyte count normal range, 1–5 × 109/l
h Monocyte percentage normal range, (3–9)
i Monocyte count normal range 0.2–0.8 × 109/l
Co-morbidities Mild, n = 22 (%) Moderate, n = 32 (%) Severe, n = 22 (%)
Allergic rhinitis
 Yes 1 (4.5) 14 (43.75) 18 (81.81)
 No 21 (95.45) 18 (56.25) 4 (18.19)
Hypertension
 Yes 0 7 (21.88) 11 (50)
 No 25 (78.12) 11 (50)
Diabetes mellitus
 Yes 0 7 (21.88) 5 (22.73)
 No 25 (78.12) 17 (77.27)
Obesity
 Yes 1 (4.5) 3 (9.38) 4 (18.19)
 No 21 (95.45) 29 (90.62) 18 (81.81)
GERD
 Yes 0 11 (34.38) 7 (31.82)
 No 21 (65.62) 15 (68.18)
Laboratory characteristics
 Total  IgEa – 32 (100) 0–100 8 (36.4) > 100
9 (40.9) > 300
5 (22.7) 500–700
 %  Eosinophilb 22 (100) 0–6 32 (100) 6.2–11 22 (100) 7.4–14
 #  Eosinophilc 22 (100) 0.2–0.8 32 (100) 9–1.23 22 (100) 1.1–1.5
 %  Neutrophild 22 (100) 40–75 28 (87.5) 40–75 20 (90.9) 40–75
2 (6.25) > 75 1 (4.55) > 75
2 (6.25) < 40 1 (4.55) < 40
 #  Neutrophile 22 (100) 2–7.5 28 (87.5) 2–7.5 21 (95.45) 2–7.5
2 (6.25) > 7.5 1 (4.55) < 2
2 (6.25) < 2
 %  Lymphocytef 22 (100) 20–45 26 (81.25) 20–45 18 (81.81) 20–45
1 (3.13) > 45 1 (4.55) > 45
5 (15.62) < 20 3 (13.64) < 20
 #  Lymphocyteg 22 (100) 1–5 30 (93.75) 1–5 20 (90.9) 1–5
2 (6.25) < 1 1 (4.55) > 5
1 (4.55) < 1
 %  Monocyteh 22 (100) 3–9 25 (78.13) 3–9 17 (77.27) 3–9
7 (21.87) > 9 5 (22.73) > 9
 #  Monocytei 22 (100) 0.2–0.8 28 (87.5) 0.2–0.8 21 (95.45) 0.2–0.8
4 (12.5) > 0.8 1 (4.55) < 0.8
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FMOs (fluorescence minus one) for each monoclonal 
antibody were prepared and run with the first batch of 
samples each week. An unstained cell suspension for 
each sample was included with each run. Appropriate 
isotype controls were also included (Table  3) to set up 
appropriate gating.
Cell surface staining
Aliquots of each cell suspension sample (100  µl) were 
incubated (30  min) at 4  °C in the dark with anti-CD45, 
anti-CD14, anti-CD16, anti-CD192 (CCR2) and anti-
CX3CR1 fluorescently conjugated monoclonal antibodies 
(Table  3). Following incubation, cells were washed with 
1  ml FACS buffer followed by centrifugation at 431×g 
for 4 min. The cell pellets were re-suspended in 500 µl of 
FACS buffer and 3×105 cells were acquired using LSRII 
flow cytometer (BD Biosciences). Data analysis was 
performed using FACS Diva software (BD Biosciences).
Gating strategy
First, forward scatter (FSC) and side scatter (SSC) dot 
plots were used to identify cells from debris. An SSC/
CD45 dot plot from a live gate was used to gate on 
 CD45+cells and exclude large granulocytes. An FSC/
SSC dot plot from the  CD45+ expressing cells was used 
to tightly gate on the monocyte population as previously 
described by our group [25]. A CD14/CD16 dot plot was 
expressed from the gated monocytes to reveal the three 
monocyte subsets  (CD14++CD16−,  CD14++CD16+, and 
 CD14+CD16++) based on their fluorescent intensity 
based on FMO and isotype controls. A CCR2/CX3CR1 
dot plot was obtained for each monocyte subset (Fig. 1).
Statistical analysis
Analysis was performed through Graph Pad PRISM 
version 6 (Graph Pad software, La Jolla, CA, USA). 
Significance was calculated using a Holm–Sidak unpaired 
comparison test. Results were considered statistically 
significant if the p value was < 0.05. Mean percentages 
are given in the text ± standard error. Correlations 
were analysed using nonparametric Spearman’s rank 
correlation coefficient.
Results
Expression of CD16 is altered on monocyte subsets 
in patients with asthma
The percentage of blood monocytes was significantly 
increased in patients with severe asthma (15 ± 2; 
p = 0.002) compared to healthy individuals (8%), while 
no significant change was observed in the patients with 
mild (9 ± 1) and moderate (7 ± 1) asthma (Fig.  2). The 
proportion of the three individual monocyte subsets 
showed no significant changes in patients with mild, 
moderate and severe asthma compared with healthy 
individuals (Fig. 2).
Our data showed that the expression level (MFI) of 
CD14 on the monocyte subsets was not significantly 
different in patients with mild, moderate and severe 
asthma compared to healthy controls (Fig. 3a). However, 
the expression level of CD16 on  CD14++CD16+ 
intermediate subset monocytes was significantly lower in 
patients with moderate (p = 0.006) and severe (p = 0.004) 
asthma and there was also a significant decrease 
(p = 0.005) in CD16 expression on the non-classical 
 CD14+CD16++ monocyte subset in patients with 
severe asthma compared to healthy controls (Fig.  3b). 
Collectively, these data demonstrated that while the 
percentage of the monocyte subsets was not significantly 
changed, there was differential expression of CD16 on 
monocyte subsets associated with asthma severity.
CCR2 and  CX3CR1 chemokine receptor expression 
is altered on monocytes from patients with asthma
Expression of CCR2, is associated with phagocytic 
monocytes [14–17]. In the non-classical  CD14+CD16++ 
subset, the percentage of monocytes expressing CCR2 
was significantly higher in the patients with mild (24 ± 3; 
p < 0.0001), moderate (16 ± 2.5; p = 0.009) and severe 
(18 ± 2.7; p = 0.002) asthma compared to healthy (9%) 
controls (Fig. 4a). The percentage of monocytes expressing 
CCR2 in the intermediate  CD14++CD16+ subset was 
significantly higher only in patients with mild (17 ± 4; 
p = 0.018) and moderate (17 ± 3; p = 0.003) asthma, 
not severe asthma, compared to healthy (7%) controls 
(Fig.  4a). The percentage of monocytes expressing CCR2 
Table 3 Fluorescently labelled antibodies for monocyte cell surface markers (all mouse anti-human antibodies except rat 
anti-human)
Epitope Conjugate Manufacturer Clone Isotype Test volume
(µl)
CD45 AF700 Becton–Dickinson HI30 IgG1, k 5
CD14 BV510 Becton–Dickinson MφP9 IgG2b, k 5
CD16 BV421 Becton–Dickinson 3G8 IgG1, k 3
CCR2 AF647 Becton–Dickinson 48607 IgG2b 5
CX3CR1 (rat anti‑human) PE MBL 2A9‑1 IgG2b, k 10
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in the classical  CD14++CD16− subset was not changed 
when patients with mild, moderate or severe asthma were 
compared with healthy controls (Fig. 4a). The MFI for CCR2 
on all monocyte subsets showed no significant difference in 
patients with mild, moderate or severe asthma compared to 
healthy controls (Fig. 4b).
Expression of  CX3CR1 is associated with patrolling 
monocytes [14–17]. In the non-classical  CD14+CD16++ 
subset, the percentage of cells expressing  CX3CR1 was 
significantly decreased in patients with mild (67 ± 4; 
p < 0.0001, moderate (74 ± 3.5; p = 0.003) or severe 
(74 ± 3.6; p = 0.003) asthma compared to healthy controls 
(85%) (Fig.  5a). A significant decrease was observed 
in the percentage of cells expressing  CX3CR1 in the 
intermediate  CD14++CD16+ subset  in patients with 
mild (75 ± 4; p = 0.002) and moderate (78 ± 3; p = 0.004) 
asthma compared to healthy (88%) controls (Fig.  5a). 
The percentage of monocytes expressing  CX3CR1 in the 
classical  CD14++CD16− subset was not changed when 
patients with mild, moderate or severe asthma were 
compared with healthy controls (Fig. 5a).  CX3CR1 MFI was 
also significantly decreased (p = 0.0146) on the non-classical 
 CD14+CD16++ subset in patients with severe asthma 
compared to healthy control subjects (Fig. 5b). Together, all 
patients with asthma demonstrated a significant (p < 0.05) 
inverse relationship between CCR2 (increased compared 
to controls) and  CX3CR1 (decreased compared to controls) 
percentage expression in the intermediate  CD14++CD16+ 
subset (Fig.  6a–c) although this relationship was weaker 
in the severely asthmatic patients (Fig.  6c). For the 
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non-classical  CD14+CD16++ subset all the patients strongly 
showed this inverse relationship with Spearman’s rank 
correlation coefficient analysis showing this to be highly 
significant (p ≤ 0.0005, Fig. 6d–f).
Discussion
In the presented work, we have studied monocytes from 
patients with asthma (all from Saudi Arabia) in terms of 
their CD14/CD16 defined subsets and expression of the 
chemokine receptors CCR2 and  CX3CR1 to determine 
whether there are monocyte characteristics that can be 
linked to asthma or to the disease severity.
Proportions of monocyte subsets did not change 
with asthma severity
Our study showed a significant increase in the percentage 
of the  CD45+ population of blood cells that were 
monocytes  (CD45+/CD14+) in patients with severe 
asthma compared to healthy controls. The observed 
increase in this percentage of monocytes in patients 
with severe asthma may reflect their higher susceptibility 
to an allergenic or stress response and subsequent 
inflammatory reaction and release of monocytes from 
bone marrow or spleen [26, 27].
Despite the increase in the percentage of the  CD45+ 
population that were monocytes, the proportions of 
classical, intermediate and non-classical monocyte 
subsets, as defined by CD14/CD16 expression, showed 
no significant difference in patients compared to healthy 
controls. While most asthma studies have focused on 
assessing the total monocyte numbers, one study in 
particular, by Moniuszko et  al. [22], demonstrated a 
significant increase in the intermediate  CD14++CD16+ 
monocyte percentage in patients with severe asthma 
compared to healthy controls or to patients with mild and 
moderate asthma [22]. Our study, however, provides no 
evidence that the proportion of this intermediate subset 
is increased with severe asthma. This may be a result of 
gating variation between the two studies; for example, 
our study gated on  CD45+ cells initially. Perhaps more 
importantly, one of the main dissimilarities is that the 
study by Moniuszko et  al. [22] involved patients from 
Poland whereas the patients in our study are from Saudi 
Arabia, where asthma may be triggered by different 
environmental factors. This suggests that differences may 
also reflect genetic or environmental factors influencing 
the distinct populations.
Decreased expression of CD16 on monocyte subsets 
in asthma
There was a significant decrease in CD16 MFI 
expression in patients with moderate and severe 
asthma in the intermediate  (CD14++CD16+) monocyte 
subset and also in the non-classical  (CD14+CD16++) 
subset in patients with severe asthma compared to 
healthy controls. Changes in CD16 MFI have not 
been investigated in previous asthma studies although 
reduction in CD16 MFI on monocytes has been 
reported in other patients, for example, in patients with 
coronary artery disease [28].
CD16+ monocytes are often expanded in inflammatory 
conditions such as sepsis and atherosclerosis [17, 21, 
29]. It has been shown with human monocyte subsets 
that monocytes are released from the bone marrow 
in an inflammatory response as classical monocytes 
and differentiate sequentially in the circulation into 
intermediate and then non-classical monocytes [30]. 
This suggests that the decreased  CD16+ expression we 
show, on intermediate and non-classical monocytes, 
associated with increased asthma severity may be due 
to the fact that monocytes are recently released from 
the bone marrow and have not yet acquired full CD16 
expression.
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Fig. 2 Comparative analysis of the percentage of  CD45+ cells, total 
monocyte population and monocyte subsets in mild asthmatic 
patients (n = 22), moderate asthmatic patients (n = 32) and severe 
asthmatic patients (n = 22) compared to healthy control patients 
(n = 35). Each monocyte subset is shown as box groups where the 
left box indicates healthy subjects and the next boxes indicate mild, 
moderate and severe asthmatic patients respectively. The box ranges 
from the 25th to 75th percentile, where the top end of the whiskers 
indicates the largest value less than the sum of 75th percentile plus 
1.5×IQR (interquartile range) and any values greater than this are 
considered outliers (represented by dots) and the bottom end of the 
whiskers indicates the lowest value greater than the 25th percentile 
minus 1.5×IQR and any values less than this are considered outliers. 
The middle line represents the median. Significance was calculated 
using Holm–Sidak unpaired multiple comparison test and is indicated 
with **(p < 0.01)
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CD16 on human monocytes is the Fc receptor, FcγRIIIa 
(CD16a) which is a low affinity IgG receptor [31] unlikely 
to promote an inflammatory response in asthma. 
However,  CD16+ monocyte subsets have distinct roles in 
the inflammatory response, with the non-classical subset 
responsible for a patrolling, ‘house-keeping’ role, able to 
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Fig. 3 Comparative analysis of CD14 expression (a) and CD16 expression (b) on monocyte subsets from mild asthmatic patients (n = 22), moderate 
asthmatic patients (n = 32) and severe asthmatic patients (n = 22) compared to healthy control (n = 35). Each monocyte subset is shown as box 
groups (as defined in Fig. 2) where the left box indicates healthy subjects and the next boxes indicate mild, moderate and severe asthmatic patients 
respectively. Gating was performed as in Fig. 1 and significance, compared to healthy controls, was calculated using Holm–Sidak unpaired multiple 
comparison test and is indicated with *(p < 0.05), **(p < 0.01)
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Fig. 4 Comparative analysis of the percentage of monocytes that are CCR2 positive (a) or CCR2 expression (MFI; b) on monocyte subsets from 
mild asthmatic patients (n = 22), moderate asthmatic patients (n = 32) and severe asthmatic patients (n = 22) compared to healthy control patients 
(n = 35). Each monocyte subset is shown as box groups (as defined in Fig. 22 where the left box indicates healthy subjects and the next boxes 
indicate mild, moderate and severe asthmatic patients respectively. Gating was performed as in Fig. 1 and significance, compared to healthy 
controls, was calculated using Holm–Sidak unpaired multiple comparison test and is indicated with **(p < 0.01), ***(p < 0.001)
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attach and crawl on endothelium and distinguish virally 
infected and damaged cells [32].
Chemokine receptor expression on monocyte subsets 
changes in patients with asthma
In addition to CD14 and CD16 surface expression, 
monocyte subpopulations can be further characterised 
based on the expression of chemokine receptors, with 
the phagocytic classical monocyte subset expressing high 
levels of CCR2 and the non-classical patrolling subset 
expressing low CCR2 and high  CX3CR1 [14, 33, 34].
In this study, analysis of the percentage of cells 
expressing CCR2 and  CX3CR1 in the intermediate and 
non-classical monocyte subsets shows a strong inverse 
correlation, with CCR2 increased and  CX3CR1 decreased, 
in patients with asthma compared to healthy controls. 
This is consistent with our finding that monocyte subsets 
have decreased  CD16+ associated with increased asthma 
severity and the suggestion that monocytes newly released 
from the bone marrow have not fully reduced CCR2 and 
acquired  CX3CR1 in addition to CD16.
CCR2 and its ligands are known to be crucial for the 
recruitment of inflammatory monocytes, enhancing 
monocyte adhesion to endothelium leading to their exit 
into the site of inflammation [35–37]. In response to 
infection CCR2-positive monocytes can be recruited in 
large numbers and in the lung in particular this can cause 
widespread damage as they appear to be less likely than 
in the skin for example to convert to M2 macrophages 
associated with wound healing and repair [38].
In the non-classical  (CD14+CD16++) monocyte subset, 
which patrols the endothelium, clearing debris and 
scanning for an inflammatory stimulus, CCR2 is down-
regulated and  CX3CR1 is highly expressed with  CX3CR1 
linked with patrolling ability and survival [18–20]. A 
general decrease in the frequency or expression of  CX3CR1 
on human monocytes has been shown in other conditions, 
for example, in patients with atopic dermatitis [39]. 
Thus these changes in CCR2 and  CX3CR1 expression in 
intermediate and non-classical monocyte subsets indicate 
a more phagocytic phenotype and increased likelihood of 
endothelial damage adversely affecting asthma progression.
One unavoidable limitation is that the patients 
included in this study were receiving treatment to reduce 
inflammation (Table 1) and it is possible that the treatment 
will have influenced monocyte characteristics. However, 
despite this, significant changes in CCR2 and  CX3CR1 
on the intermediate and non-classical monocyte subsets 
were still evident however, whether they are a cause or 
consequence of disease remains to be established.
Conclusions
This differential expression of CD16,  CX3CR1 and CCR2 
on the monocyte subsets in peripheral blood indicates that 
monocytes may modulate the inflammatory response in 
asthma. The increase in CCR2 expression and decrease in 
 CX3CR1 on  CD16+ monocytes has not, to our knowledge, 
been described before in asthma and this association 
suggests a role for monocytes in asthma pathogenesis.
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